Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06144723 | Study of HS-20105 for Injection in Patients With Advanced Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 402 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
| NCT06134531 | First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors | not yet recruiting | Phase 1 | 31 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06132217 | A Study of Simmitinib Plus SG001 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 168 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06026501 | A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor | not yet recruiting | Phase 1 / Phase 2 | 120 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Sep 7, 2023 | clinicaltrials |
| NCT05788107 | Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma | not yet recruiting | Phase 1 | 30 | Shanghai Henlius BiotechINDUSTRY | 0 | Aug 9, 2023 | clinicaltrials |
| NCT05940116 | A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 322 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05361954 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 36 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Apr 12, 2023 | clinicaltrials |
| NCT05804864 | A Study of KM501 in Patients With Solid Tumors | not yet recruiting | Phase 1 | 96 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05766527 | A Study of KM602 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 38 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05320874 | A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors. | not yet recruiting | Phase 1 | 232 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 11, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Nov 22, 2023source: clinicaltrials